3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Genitourinary
1
Gastrointestinal
1
Breast
1
Conditions
Prostatic Neoplasms
195
Prostatic Neoplasms, Castration-Resistant
20
Neoplasm Metastasis
20
Metastatic Castration Resistant Prostate Cancer
10
Prostate Cancer Metastatic
7
Metastatic Castration-Resistant Prostate Cancer
7
Metastatic Castration-resistant Prostate Cancer
6
Neoplasms
5
Castration-resistant Prostate Cancer
5
Breast Neoplasms
5
Pancreatic Neoplasms
4
Melanoma
4
Colorectal Neoplasms
4
Carcinoma, Non-Small-Cell Lung
4
Bulbo-Spinal Atrophy, X-Linked
4
Adenocarcinoma
4
Urinary Bladder Neoplasms
3
Prostate Adenocarcinoma
3
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Carcinoma, Renal Cell
3
Carcinoma, Hepatocellular
3
Uterine Cervical Neoplasms
2
Triple Negative Breast Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
2
Small Cell Lung Carcinoma
2
Prostatic Diseases
2
Ovarian Neoplasms
2
Non-metastatic Castration-resistant Prostate Cancer
2
Metastatic Hormone-sensitive Prostate Cancer
2
Metastatic Hormone Sensitive Prostate Cancer
2
Interventions
pembrolizumab
3
tislelizumab
1
spartalizumab
1
milademetan
1
enzalutamide
1
devimistat
1
dehydroftorafur
1
Tablets
1
Specimen Handling
1
Solutions
1
Rogaratinib
1
Pemetrexed
1
Midazolam
1
Magnetic Resonance Spectroscopy
1
Letrozole
1
IFL protocol
1
Hydroxychloroquine
1
Gemcitabine
1
Fulvestrant
1
Fluorouracil
1
Cetuximab
1
Carboplatin
1
BID protein, human
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma of Lung
×
enzalutamide
×
Genitourinary
×
Clear all
NCT04557449
2025-10-01
CDK4i
Pfizer
Phase 2
Active not recruiting
362 enrolled